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Abstract
Background: Helicobacter pylori (HP) infection is present in about 50% of the global population, and is associated
with chronic gastritis, peptic disease and gastric malignancies. HP prevalence in Crohn’s disease (CD) patients was
shown to be low compared to the general population, and its influence on disease activity is yet to be determined.
Our aims were to determine the prevalence of HP in a selected group of CD patients with quiescent disease, and
to assess the influence of its eradication on disease activity and endoscopic and laboratory activity measures.
Methods: Consecutive CD patients with quiescent disease underwent meticulous disease evaluation with MR
enterography (MRE), video capsule endoscopy (VCE), CRP, fecal calprotectin and CDAI. All patients were tested for
the presence of HP using stool antigen detection kit. Patients infected with HP were offered eradication treatment
with sequential therapy. HP eradication was confirmed using urease breath test and stool antigen test. The influence of
HP eradication on disease activity was assessed.
Results: Out of 56 patients enrolled, six patients (10.7%) had HP infection. Of them, five patients had gastro- duodenitis
per VCE. All HP positive patients were offered eradication treatment and underwent successful eradication.
Notably, 23 (50%) of patients had proximal disease per VCE, most of them (78%) were HP negative.
CDAI, CRP, fecal calprotectin and VCE Lewis inflammatory score did not change significantly following HP
eradication, Gastric findings on VCE were not impacted by HP eradication.
Conclusions: The prevalence of HP infection in patients with quiescent CD is relatively low. Eradication of the
bacteria did not significantly change neither disease activity measures nor the presence of gastro- duodenitis per VCE,
suggesting it might be part of proximal CD. The influence of HP on CD activity merits further investigation.
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Background
Helicobacter pylori (HP) infection is one of the most
prevailing global pathogens in humans, and can be
detected in 50% of the world’s population [1]. Its preva-
lence varies considerably in association by geography,
ethnicity, age, and socioeconomic factors.
This Gram- negative bacterium causes chronic inflam-
mation in the gastric mucosa, which leads to atrophic
and metaplastic changes. Thus, HP infection is associ-
ated with chronic gastritis, peptic disease and gastric
malignancies [2, 3]. Crohn’s disease (CD) is a chronic in-
flammatory condition that can affect the gastrointestinal
system from the mouth to the anus. Inflammation is
transmural, and therefore may be cause internal ab-
scesses, fistula between adjacent organs, spontaneous
viscous perforations and fibrotic strictures.. The disease
may cause significant morbidity and diminished life
quality [4–8]. Disease behavior is characterized by periods
of flare-ups with active symptomatic disease and periods
of remission [9]. Over the years, many epidemiological
* Correspondence: zokadi@gmail.com
†Equal contributors
1Department of Gastroenterology, Sheba Medical Center, Tel Hashomer, Tel
Hashomer, Israel
2Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Lahat et al. BMC Gastroenterology  (2017) 17:27 
DOI 10.1186/s12876-017-0588-7
studies showed low incidence of HP infection in patients
with CD [10–18].
A recent meta-analysis demonstrated negative associ-
ation between HP infection and CD with OR of 0.38
(95% CI 0.31 to 0.47, p value <1e-10) [19].
The reason for that negative association is yet to
be determined. One hypothesis suggests that medica-
tions used for CD treatment may eradicate HP. An-
other suggestion along the same line is that CD
mucosal alterations might prevent HP colonization
[14, 15, 18–22]. An alternative argument suggests a
protective effect for HP infection from the occur-
rence of CD.
CD is categorized by selectively activation of type 1 T
helper lymphocyte (Th1) and Th17-related cytokines in-
volved in innate immunity (interleukin (IL) 12, IL-23,
IL-27) [23]. HP was shown to produce IL-18 which
causes accumulation of tolerogenic dendritic cells and
highly suppressive regulatory T cells (Tregs) that help
suppress the inflammatory process [24].
High frequency of gastritis and duodenitis was
described in CD patients with no association to HP in-
fection [20–22]. However, data assessing the effect of HP
infection and eradication on proximal disease and on
disease activity in patients with CD is scarce.
Thus, in our study we focused on patients with known
quiescent Crohn’s disease that were prospectively evalu-




Study population consisted of adult (>18 years) CD
patients with known small bowel Crohn’s disease in
clinical remission, as determined by the validated
Crohn’s disease activity index (CDAI) of <150, or pa-
tients suffering from mild disease symptoms, pre-
sented by CDAI of 150–220. All patients included
were treated with stable medication doses and on
corticosteroid-free remission for 3–24 months. Pa-
tients maintained on constant treatment throughout
study duration.
Patients that were unable to provide informed consent
were excluded from the study. Patients with severe co-
morbidities or with any condition that will prevent them
from swallowing VCE (difficulty in swallowing, history
of aspirations or dysphagia, known or suspected intes-
tinal obstruction or severe bowel stricturing) or under-
going MRE (claustrophobia or implanted metal objects
or cardiac pacemaker) were excluded as well.
Imaging studies
All patients underwent an MRE upon enrollment.
MR image acquisition was performed using a
previously described protocol [25]. A patency capsule
(PC) test was performed in all patients with active
small bowel disease detected on MRE. If the PC was
not expelled from the small bowel within 30 h, the
patient was withdrawn from the study. Mucosal in-
flammation was quantified using the Lewis inflam-
matory score (LS). Active inflammation was defined
as a segmental Lewis score of ≥135 [26]. A board-
certified gastroenterologist with over 10 years of
experience in capsule endoscopy read the capsule
videos. Gastric and duodenal findings were described
for each study.
Inflammatory biomarkers and disease activity measures
Fecal calprotectin, CRP and complete blood count
(CBC) were measured routinely every 3 months.
Fecal calprotectin levels were measured using the
Quantum blue calprotectin kit (BÜHLMANN Labo-
ratories AG, Basel, Switzerland). The reported value
range is 30 to 300 μg/g. Levels above 100 μg/g were
considered positive. CRP levels were considered ele-
vated if > 5 mg/l.
Patients underwent physician’s evaluation and CDAI
assessment for disease activity every 3 months.
HP assessment and treatment
All patients were tested for the presence of HP using
stool antigen detection kit as part (CerTest H. pylori
one step card test, Certest Biotec S.L. Zaragoza, Spain).
Stool antigen test was chosen for HP detection since
this method is noninvasive and most importantly is
not influenced by antibiotics or Proton Pump Inhibi-
tors (PPI) treatment. This kit has a sensitivity of >94%,
pecificity of >99% and Positive predictive value (PPV)
of >99% for HP detection. Patients infected with HP
were offered eradication treatment with sequential
therapy consisted of 5 days of esomeprazole (40 mg)
and amoxicillin (1000 mg) twice daily, followed by
5 days of esomeprazole (40 mg), clarithromycin
(500 mg) and Tinidazole (500 mg) twice daily [27].
Notably, sequential therapy is the standard of care for
patients infected with HP in our institution. Prior to
eradication treatment patients received detailed explan-
ation regarding HP infection implications and the import-
ance of compliance and adherence to treatment. HP
eradication was confirmed using urease breath test and
stool antigen detection kit 4 weeks following eradication
treatment completion.
The impact of HP eradication on disease activity and
degree of proximal small bowel inflammation was
assessed using the disease activity measures specified
above, 8 weeks after eradication conformation.
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Statistical analysis
Descriptive statistics were presented as means ± standard
deviations for continuous variables and percentages for
categorical variables. Categorical variables were ana-
lyzed by Chi Square/Fisher’s exact test and continuous
variables-by T-test/Mann Whitney test, as appropriate.
P < 0.05 was considered significant. All computations
were performed with the MedCalc Software (Marieke,
Belgium).
Results
Fifty six patients were included in the study. Patients’
demographic data and disease characteristics are shown
in Table 1. None of the patients was tested for HP prior
to this study. A schematic graph of study design is
shown in Fig. 1.
Out of all patients included, only six patients (10.7%)
were infected with HP. Of them, five patients had
gastro- duodenitis per VCE and one had no proximal
disease and no upper GI symptoms. All HP positive
patients were offered eradication treatment with se-
quential therapy detailed above. All infected patients
agreed to receive eradication treatment, and all treated
patients underwent successful eradication, as was
confirmed by a negative urease test and negative stool
antigen test. Thus, a 100% eradication rate was
achieved.
Notably, 23 (50%) of patients had proximal disease per
VCE, most of them (78%) were HP negative.
Four weeks after a verified eradication, a repeated
evaluation of disease activity was performed. Physical
examination, CBC, CRP was performed and CDAI
was calculated. Capsule endoscopy was ingested as
well 12 weeks following eradication. Disease activity
measures before and 12 weeks following HP eradica-
tion in all patients treated was compared, and are
shown in Table 2. A separate analysis was performed
only for patients who had gastro-duodenitis per VCE
before HP eradication. Results are shown in Table 3.
As shown in Tables 2 and 3, all disease activity measures
as well as anatomical disease distribution (measured by
VCE Lewis inflammatory score) were unchanged fol-
lowing HP eradication. Hence, HP eradication had no
influence on disease activity.
Figures 2a, b and 3a, b show active CD in the proximal
digestive system demonstrated by mucosal erosions in
stomach and duodenum - unchanged before and after
eradication treatment, respectively.
Discussion
HP infection is one of the most prevalent infectious
diseases worldwide. However, in CD patients its preva-
lence was shown to be lower than in general population
[10–18]. The reason for that remains to be determined,
as is the mutual impact of CD and HP infection on pa-
tients’ symptoms, severity of the disease and on disease
distribution. In the current study, we initially assessed
the prevalence of HP infection in a homogenous group
of CD patients with quiescent disease, and then tried to
assess prospectively the impact of HP eradication on
disease activity measures and on anatomical inflamma-
tory distribution.
In agreement with data in the literature [10–18], HP
infection rate was low among our patients’ group, with
only 11% of patients tested positive to HP. The current
prevalence of HP infection in Israel is unknown, yet data
from 2002 [28] suggest a 60% prevalence among the
general population in Israel. Thus, even if we assume a
possible reduction in HP infection in the general popula-
tion during the last decade, HP infection among CD pa-
tients is still significantly low. Notably, none of our
patients was tested for the presence of HP before enter-
ing the study, and consequently none was ever treated
for HP eradication. Therefore, we believe that our data
reflects the true prevalence of HP infection in CD
patients.
All the patients who tested positive for HP were of-
fered eradication treatment, though one of them was a-
symptomatic. Since HP is a well known carcinogen with
a strong proven relation to gastric malignancy [2, 3],
we decided to offer eradication treatment to all infected
patients.
In order to achieve maximal eradication rates pa-
tients were treated with a 10 day sequential therapy,
which was shown to have eradication success of up
to 94% [29].
In addition, at treatment initiation patients received
individual consultation with emphasis on the importance
Table 1 Patients’ demographic data and disease characteristics
Number Percent
Male/female 30/26 53.6/46.4
Age at diagnosis (years) 26 ± 11
Disease duration (years) 6 ± 5
Clinical remission 52 92.3
Smoking status current 11 19.6
never smoked 36 64.3
past smoking 9 16.1
Previous surgery 9 16.1








No medical treatment 11 19.6
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of compliance and adherence to the offered treatment.
Eradication was verified both with urease breath test and
with stool antigen detection kit. Using this meticulous
treatment option, we managed to reach a 100% eradica-
tion rate.
Obviously, since our treatment group consisted of 6
patients only, the results are underpowered to assess
treatments’ efficacy. However, we believe that the
combination of a high- efficacy eradication protocol
and highly motivated patients with high compliance
rates probably lead to this unusually high eradication
rate.
Eradication was verified using breath test and stool
antigen kit 4 weeks following treatment completion [30].
Eight weeks following eradication verification, patients
underwent repeated disease evaluation, including VCE.
Data in literature support repeated endoscopy for peptic
disease 4 weeks following HP eradication treatment [31].
Therefore, we postulated that 8 weeks following eradi-
cation verification and 12 weeks following end of
eradication treatment is appropriate for reevaluation,
assuming that all mucosal damage caused by HP would
be healed.
Our results show no improvement in proximal disease
or in disease measures following HP eradication. Hence,
CDAI, CRP and fecal calprotectin levels did not differ
significantly after HP eradication, implicating disease ac-
tivity was unchanged following eradication. Moreover,
Table 2 Disease activity measures in all HP positive patients
before and after eradication (n = 6)
Disease measures Before eradication After eradication p
CDAI 27.5 ± 21.25 22.83 ± 28.25 NS
CRP 1.17 ± 0.82 2.97 ± 4.7 NS
Fecal calprotectin 75 ± 79.37 112.17 ± 123.2 NS
Lewis Score 425 ± 334.29 564.83 ± 529.46 NS
NS non-significant
Table 3 Disease activity measures in HP positive patients with
gastroduodenitis on VCE before and after eradication (n = 5)
Disease measures Before eradication After eradication p
CDAI 23.18 ± 25.6 30.91 ± 25.2 NS
CRP 1.218 ± 0.9 5.12 ± 3.398 NS
Fecal calprotectin 85 ± 85.25 74.6 ± 71.57 NS
Lewis Score 357.33 ± 465 587.995 ± 589.8 NS
NS non-significant
Fig. 1 Study design
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the VCE Lewis inflammatory score, as a measure of
disease activity and distribution was showed no statisti-
cally significant improvement following HP eradication
as well. These results were unchanged after separate
sub analysis of patients with gastro-duodenitis per
VCE.
These data implicates that the proximal disease as
well as disease activity was unrelated to HP. To the best
of our knowledge, up to date, no study addressed dis-
ease activity measures pre versus post HP eradication
in CD patients.
In our study, 50% of patients had gastro-duodenitis
per VCE. These results are in agreement with previous
studies that showed an increased prevalence of gastro-
duodenitis disease in CD patients with no association to
HP infection [20–22].
Our study has several limitations. First, our cohort
of patients was relatively small. Therefore, due to the
low prevalence of HP infection in CD patients, the
number of HP infected patients was very low. The
small number of patients included might affect the ap-
plicability of our results.
Another theoretical drawback of our study is a selec-
tion bias- only patients with quiescent disease were in-
cluded, thus patients with active CD might have had
different results.
However, we feel that our data supports the
evidence showing high incidence of gastroduodenitis
in patients with quiescent CD, unrelated to HP
infection.
Conclusions
HP infection in patients with quiescent CD is lower
than in the general population, and reaches 11%.
Eradication of the bacteria did not change significantly
neither disease measures nor the presence of gastro- duo-
denitis per VCE, suggesting it might be part of proximal
CD. The influence of HP on CD activity merits further
investigation.
Fig. 2 Stomach inflammatory changes by VCE. a Gastric erosions (circled) prior to HP eradication. b Gastric erosions (circled) post HP eradication
Fig. 3 Duodenum inflammatory changes by VCE0. a Erosion of proximal duodenum (circled) Prior to HP eradication. b Erosions in proximal
duodenum (circled) Post HP eradication
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